When did Stevanato go public?
Stevanato Group S.p.A., a global leader in providing containment, drug delivery, and diagnostic solutions for the pharmaceutical and biotechnology industries, officially completed its initial public offering on the New York Stock Exchange under the ticker symbol STVN on July 16, 2021. The international enterprise priced its shares to raise substantial institutional capital, which was allocated toward expanding its high-precision manufacturing facilities, advancing proprietary glass and polymer technologies, and scaling its worldwide cleanroom production capabilities.
Related FAQs
CIR S.p.A. (Compagnie Industriali Riunite) shares trade on Euronext Milan under ticker CIRI at approximately €0.719 per share.
Tod's S.p.A.
The GEO Group, Inc.
Tod's S.p.A.
Stevanato Group S.p.A. trades on the New York Stock Exchange under the ticker symbol STVN at a market price of approximately $19.85 per share.
As of July 26, 2026, the estimated net worth of Steven Roth is at least $422 million, primarily based on his substantial insider holdings in Vornado Realty Trust and other real estate entities.
Beam Therapeutics officially completed its initial public offering and began trading its shares on the Nasdaq Global Select Market under the ticker symbol BEAM on February 6, 2020.
Stevanato Group SpA, trading under the ticker symbol STVN, is frequently viewed by equity analysts as a compelling purchase, supported by strong global demand for specialized containment and delivery systems for the biopharmaceutical industry.
Stevanato Group S.p.A.
STVN represents the stock ticker symbol or corporate shorthand for various emerging biotechnology or pharmaceutical entities—most notably specialized clinical-stage therapeutic firms focusing on novel treatments for genetic, metabolic, or oncological...